SCHEMBL3098671

SCHEMBL3098671

CCc1oc(-c2ccccc2)cc1CO

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
KDM4E B2RXH2 2/20 0.44
NOTUM Q6P988 2/20 0.41
PDCD1 Q15116 1/20 0.40
CD274 Q9NZQ7 1/20 0.40
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
NPC1 O15118 1/20 0.38
CA12 O43570 1/20 0.38
TNKS O95271 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
TP53 P04637 1/20 0.38
ABCB1 P08183 1/20 0.38
CYP3A4 P08684 1/20 0.38
PARP1 P09874 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
AR P10275 1/20 0.38
CYP19A1 P11511 1/20 0.38
GABRA1 P14867 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3112801 0.82 CYP3A4 (0.42) ALDH1A1KDM4ENOTUMGABRPGABRD
SCHEMBL3104717 0.82 ALDH1A1 (0.41) ALDH1A1KDM4ENOTUMPDCD1CD274
SCHEMBL3110166 0.81 EGFR (0.49) ALDH1A1KDM4ENPC1TNKSTP53
SCHEMBL3903128 0.81 KDM4E (0.46) ALDH1A1KDM4ENPC1TP53CYP3A4
SCHEMBL3069277 0.79 PDCD1 (0.46) ALDH1A1KDM4ENOTUMPDCD1CD274
SCHEMBL14848452 0.75 NOTUM (0.44) ALDH1A1KDM4ENOTUMPDCD1CD274
SCHEMBL12603818 0.73 MAOB (0.43) ALDH1A1KDM4EGABRPGABRDNPC1
SCHEMBL4348247 0.73 KDM4E (0.50) ALDH1A1KDM4EGABRPGABRDNPC1
SCHEMBL3095566 0.72 ALDH1A1 (0.38) ALDH1A1KDM4ENPC1CA12CA1
SCHEMBL3104730 0.71 ALDH1A1 (0.43) ALDH1A1KDM4EGABRPGABRDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR ALDH1A1 3963/4885KDM4E 2280/4885NOTUM 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.